Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

BACKGROUND: Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been associated with ligand-independent transcription of ER. We have previously rep...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res
Main Authors: Pancholi, Sunil, Leal, Mariana Ferreira, Ribas, Ricardo, Simigdala, Nikiana, Schuster, Eugene, Chateau-Joubert, Sophie, Zabaglo, Lila, Hills, Margaret, Dodson, Andrew, Gao, Qiong, Johnston, Stephen R., Dowsett, Mitch, Cosulich, Sabina C., Maragoni, Elisabetta, Martin, Lesley-Ann
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6894349/
https://ncbi.nlm.nih.gov/pubmed/31801615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1222-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares